Skip to main content
Premium Trial:

Request an Annual Quote

Tara Biosystems Formed to Develop Organ-on-a-Chip Technology

NEW YORK (GenomeWeb) – VC firm Harris & Harris Group today announced the formation of Tara Biosystems, which is developing organ-on-a-chip technology for evaluating new therapies and drug compounds.

Harris & Harris has invested an undisclosed amount into Tara Bio. The company will initially use its organ-on-a-chip platform to provide physiologically relevant heart-on-a-chip human tissue models for toxicology and new drug discovery applications.

Its technology comes from research done at Columbia University, the laboratory of Milica Radisic at the University of Toronto, and the Massachusetts Institute of Technology. Tara Bio has developed a stem cell-derived system based on its proprietary "biowire" technology that enables testing on 3D heart tissue for evaluating the safety and efficacy of investigational therapies. The technology reduces risks, uncertainty, and costs and potentially could accelerate the process to bring therapies with value to market, Harris & Harris said.

Filed under

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.